Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    August 2022
  1. ALZUA GP, Pihl AF, Offersgaard A, Duarte Hernandez CR, et al
    Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
    Gut. 2022 Aug 2. pii: gutjnl-2021-326323. doi: 10.1136/gutjnl-2021-326323.
    PubMed     Abstract available


  2. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.
    PubMed    


    July 2022
  3. WIGGINS BG, Pallett LJ, Li X, Davies SP, et al
    The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations.
    Gut. 2022;71:1399-1411.
    PubMed     Abstract available


    May 2022
  4. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    PubMed     Abstract available


  5. GORGULU E, Gu W, Trebicka J, Mucke VT, et al
    Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?
    Gut. 2022;71:1036-1038.
    PubMed    


    February 2022
  6. ALLWEISS L, Giersch K, Pirosu A, Volz T, et al
    Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.
    Gut. 2022;71:372-381.
    PubMed     Abstract available


    January 2022
  7. LI J, Liang X, Jiang J, Yang L, et al
    PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
    Gut. 2022;71:163-175.
    PubMed     Abstract available


    October 2021
  8. ALIABADI E, Urbanek-Quaing M, Maasoumy B, Bremer B, et al
    Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection.
    Gut. 2021 Oct 26. pii: gutjnl-2021-324646. doi: 10.1136/gutjnl-2021-324646.
    PubMed     Abstract available


  9. HSU YC, Tseng CH, Su TH, Kao JH, et al
    Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities.
    Gut. 2021 Oct 20. pii: gutjnl-2021-326232. doi: 10.1136/gutjnl-2021-326232.
    PubMed    


  10. TRIVEDI PJ, Hirschfield GM
    Recent advances in clinical practice: epidemiology of autoimmune liver diseases.
    Gut. 2021;70:1989-2003.
    PubMed     Abstract available


    September 2021
  11. HALL SAL, Vogrin S, Wawryk O, Burns GS, et al
    Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
    Gut. 2021 Sep 7. pii: gutjnl-2020-323979. doi: 10.1136/gutjnl-2020-323979.
    PubMed     Abstract available


    June 2021
  12. URBAN S, Neumann-Haefelin C, Lampertico P
    Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
    Gut. 2021 Jun 8. pii: gutjnl-2020-323888. doi: 10.1136/gutjnl-2020-323888.
    PubMed     Abstract available


    May 2021
  13. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available


  14. JINDAL A, Vyas A, Dubey G
    Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil.
    Gut. 2021 May 5. pii: gutjnl-2021-324967. doi: 10.1136/gutjnl-2021-324967.
    PubMed    


    April 2021
  15. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
    HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
    PubMed     Abstract available


    March 2021
  16. PAN CQ, Dai E, Duan Z, Han G, et al
    Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.
    Gut. 2021 Mar 31. pii: gutjnl-2020-322719. doi: 10.1136/gutjnl-2020-322719.
    PubMed     Abstract available


  17. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.
    PubMed    


  18. YUEN MF, Wong DK, Schluep T, Lai CL, et al
    Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment.
    Gut. 2021 Mar 12. pii: gutjnl-2020-323445. doi: 10.1136/gutjnl-2020-323445.
    PubMed     Abstract available


  19. LI J, Li J, Chen S, Yuan Q, et al
    Naturally occurring 5' preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C.
    Gut. 2021;70:575-584.
    PubMed     Abstract available


    February 2021
  20. PENEAU C, Imbeaud S, La Bella T, Hirsch TZ, et al
    Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
    Gut. 2021 Feb 9. pii: gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153.
    PubMed     Abstract available


  21. WIJAYA RS, Read SA, Truong NR, Han S, et al
    HBV vaccination and HBV infection induces HBV-specific natural killer cell memory.
    Gut. 2021;70:357-369.
    PubMed     Abstract available


    January 2021
  22. BUKH J
    Vaccines against hepatitis C: a travel into neutralisation space.
    Gut. 2021 Jan 25. pii: gutjnl-2020-323377. doi: 10.1136/gutjnl-2020-323377.
    PubMed    


  23. LIU CH, Chen CY, Su WW, Tseng KC, et al
    Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Gut. 2021 Jan 6. pii: gutjnl-2020-323569. doi: 10.1136/gutjnl-2020-323569.
    PubMed     Abstract available


    December 2020
  24. SVICHER V, Salpini R, Piermatteo L, Carioti L, et al
    Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.
    Gut. 2020 Dec 21. pii: gutjnl-2020-323300. doi: 10.1136/gutjnl-2020-323300.
    PubMed     Abstract available


  25. BANKWITZ D, Bahai A, Labuhn M, Doepke M, et al
    Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Gut. 2020 Dec 15. pii: gutjnl-2020-321190. doi: 10.1136/gutjnl-2020-321190.
    PubMed     Abstract available


  26. YU ML, Huang CF, Wei YJ, Lin WY, et al
    Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut. 2020 Dec 10. pii: gutjnl-2020-323277. doi: 10.1136/gutjnl-2020-323277.
    PubMed     Abstract available


  27. SONG S, Shi Y, Wu W, Wu H, et al
    Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
    Gut. 2020 Dec 10. pii: gutjnl-2020-321386. doi: 10.1136/gutjnl-2020-321386.
    PubMed     Abstract available


  28. KIM MA, Kim SU, Sinn DH, Jang JW, et al
    Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Gut. 2020;69:2214-2222.
    PubMed     Abstract available


    November 2020
  29. KIM HL, Kim GA, Park JA, Kang HR, et al
    Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Gut. 2020 Nov 25. pii: gutjnl-2020-321309. doi: 10.1136/gutjnl-2020-321309.
    PubMed     Abstract available


  30. TAKEUCHI M, Vidigal PT, Guerra MT, Hundt MA, et al
    Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322540. doi: 10.1136/gutjnl-2020-322540.
    PubMed     Abstract available


  31. ZENG G, Gill US, Kennedy PTF
    Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis.
    Gut. 2020;69:1907-1912.
    PubMed    


    October 2020
  32. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    PubMed     Abstract available


    September 2020
  33. LIU K, Peng P, Cai F, Huang J, et al
    Comparison of the long-term efficacy between tenofovir and entecavir in chronic hepatitis B patients.
    Gut. 2020 Sep 14. pii: gutjnl-2020-322642. doi: 10.1136/gutjnl-2020-322642.
    PubMed    


  34. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available


    August 2020
  35. SETO WK, Liu KS, Mak LY, Cloherty G, et al
    Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.
    Gut. 2020 Aug 5. pii: gutjnl-2020-321116. doi: 10.1136/gutjnl-2020-321116.
    PubMed     Abstract available


    July 2020
  36. HOFMANN M, Thimme R
    Hepatitis B vaccine and NK cells: a new player in memory.
    Gut. 2020 Jul 15. pii: gutjnl-2020-321151. doi: 10.1136/gutjnl-2020-321151.
    PubMed    


    June 2020
  37. CARGILL Z, Brown SE, Dusheiko G, Agarwal K, et al
    Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
    Gut. 2020 Jun 30. pii: gutjnl-2020-322181. doi: 10.1136/gutjnl-2020-322181.
    PubMed    


  38. ZOLDAN K, Hofmann M
    B protected: from vertical HCV transmission?
    Gut. 2020 Jun 30. pii: gutjnl-2020-321364. doi: 10.1136/gutjnl-2020-321364.
    PubMed    


  39. HORVATITS T, Varwig-Janssen D, Schulze Zur Wiesch J, Lubke R, et al
    No link between male infertility and HEV genotype 3 infection.
    Gut. 2020;69:1150-1151.
    PubMed    


    April 2020
  40. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.
    PubMed    


  41. LUTCKII A, Strunz B, Zhirkov A, Filipovich O, et al
    Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.
    Gut. 2020 Apr 27. pii: gutjnl-2019-320269. doi: 10.1136/gutjnl-2019-320269.
    PubMed     Abstract available


    March 2020
  42. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    PubMed     Abstract available


  43. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available


  44. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    PubMed     Abstract available


  45. YOUNOSSI ZM, Stepanova M, Younossi Y, Golabi P, et al
    Epidemiology of chronic liver diseases in the USA in the past three decades.
    Gut. 2020;69:564-568.
    PubMed     Abstract available


    December 2019
  46. TENG YX, Li MJ, Xiang BD, Zhong JH, et al
    Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-320326. doi: 10.1136/gutjnl-2019-320326.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: